Type 2 Diabetes (T2D) Clinical Trials

Find Type 2 Diabetes (T2D) Clinical Trials Near You

Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• eligible for bariatric surgery according to NICE guidelines (GC 189)

• Type 2 diabetes mellitus

• BMI \>30kg/m2

Locations
Other Locations
Ireland
University College Dublin
RECRUITING
Dublin
Contact Information
Primary
Alexander Miras, MRCP
a.miras@nhs.net
: +44 (0)20 8383 3242
Time Frame
Start Date: 2021-04-01
Estimated Completion Date: 2027-08-01
Participants
Target number of participants: 150
Treatments
Active_comparator: Control
Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner
Experimental: Intervention
Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.
Related Therapeutic Areas
Sponsors
Leads: Imperial College London

This content was sourced from clinicaltrials.gov